Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,preMarketChange,preMarketChangePercent,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,preMarketTime,preMarketPrice,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,IQV,-11561000000.0,191660992,,,223000000,,175000000,482000000,1115000000,290000000,290000000,,-94000000,,,,48000000,3438000000,3148000000,2323000000,-67000000,,175000000,175000000,4770000000.0,10693000000.0,18177000000.0,5760000000.0,1916000000.0,23937000000.0,3000000.0,634000000.0,1664000000.0,831000000.0,12551000000.0,-6600000000.0,490000000.0,1807000000.0,4819000000.0,105000000.0,147000000.0,-327000000.0,900000000.0,5068000000.0,158000000.0,104000000.0,2345000000.0,12182000000.0,2756000000.0,7000000,0,-185000000,-36000000,-863000000,-154000000,-498000000,-45000000,11000000,539000000,343000000,-1000000,139000000,-782000000,31000000,-145000000,249000000.0,en-US,US,EQUITY,True,Delayed Quote,USD,"IQVIA Holdings, Inc.",0.15300392,50259263488,26.595337,8.439975,15,America/New_York,EDT,-14400000,False,False,PRE,0,2,4.319977,1.6473999,262.23,1630526573,2.5,260.01,263.05,258.48,497947,NYQ,us_market,1630570149,266.55,0.962538,258.48 - 263.05,259.73,0.0,0.0,8,8,finmb_137473239,NYSE,IQVIA Holdings Inc.,USD,886662,545057,116.23001,0.79609597,146.0 - 263.61,-1.3799744,-0.0052349092,146.0,263.61,1619094600,1634560200,1634905800,124.87144,2.1,9.86,8.83,29.697622,31.07,250.42114,11.808868,0.047156036,227.43202,34.79799,1.45,,,263.61,146.0,250.42,227.43,886.66k,545.06k,191.66M,,190.23M,0.72%,91.22%,2.63M,2.55,1.56%,1.38%,2.59M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",4.69%,9.02%,3.09%,10.85%,12.93B,67.54,36.40%,3.86B,2.23B,607M,2.10,,1.91B,9.97,12.67B,220.04,1.05,31.07,2.73B,2.34B,Value,06810,Healthcare,74000,10,5,"IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",Danbury,203 448 4600,CT,9,1609372800,1625097600,10,United States,http://www.iqvia.com,86400,10,83 Wooster Heights Road,Diagnostics & Research
t-1,IQV,-11377000000.0,191660992,,,261000000,284000000.0,212000000,442000000,1116000000,351000000,351000000,,-99000000,,,,44000000,3409000000,3058000000,2293000000,-90000000,,217000000,212000000,4915000000.0,11065000000.0,18230000000.0,5953000000.0,1905000000.0,24467000000.0,3000000.0,593000000.0,1489000000.0,879000000.0,12415000000.0,-6604000000.0,487000000.0,2305000000.0,4868000000.0,107000000.0,144000000.0,-376000000.0,909000000.0,5579000000.0,162000000.0,97000000.0,2425000000.0,12136000000.0,2819000000.0,-9000000,0,-176000000,-7000000,-168000000,-12000000,491000000,-62000000,-32000000,867000000,323000000,1000000,342000000,-99000000,-3000000,-149000000,711000000.0,en-US,US,EQUITY,True,Delayed Quote,USD,"IQVIA Holdings, Inc.",0.15300392,50259263488,26.595337,8.439975,15,America/New_York,EDT,-14400000,False,False,PRE,0,2,4.319977,1.6473999,262.23,1630526573,2.5,260.01,263.05,258.48,497947,NYQ,us_market,1630570149,266.55,0.962538,258.48 - 263.05,259.73,0.0,0.0,8,8,finmb_137473239,NYSE,IQVIA Holdings Inc.,USD,886662,545057,116.23001,0.79609597,146.0 - 263.61,-1.3799744,-0.0052349092,146.0,263.61,1619094600,1634560200,1634905800,124.87144,2.1,9.86,8.83,29.697622,31.07,250.42114,11.808868,0.047156036,227.43202,34.79799,1.45,,,263.61,146.0,250.42,227.43,886.66k,545.06k,191.66M,,190.23M,0.72%,91.22%,2.63M,2.55,1.56%,1.38%,2.59M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",4.69%,9.02%,3.09%,10.85%,12.93B,67.54,36.40%,3.86B,2.23B,607M,2.10,,1.91B,9.97,12.67B,220.04,1.05,31.07,2.73B,2.34B,Value,06810,Healthcare,74000,10,5,"IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",Danbury,203 448 4600,CT,9,1609372800,1625097600,10,United States,http://www.iqvia.com,86400,10,83 Wooster Heights Road,Diagnostics & Research
t-2,IQV,-11858000000.0,191660992,,,193000000,279000000.0,119000000,464000000,1126000000,318000000,318000000,,-102000000,,,,63000000,3298000000,2980000000,2172000000,-125000000,,130000000,119000000,5205000000.0,11092000000.0,18284000000.0,6001000000.0,2401000000.0,24564000000.0,3000000.0,563000000.0,1277000000.0,793000000.0,12654000000.0,-6371000000.0,500000000.0,1814000000.0,4558000000.0,114000000.0,149000000.0,-205000000.0,953000000.0,5090000000.0,162000000.0,88000000.0,2466000000.0,12440000000.0,581000000.0,1000000,433000000,-236000000,-97000000,-198000000,-9000000,350000000,-101000000,34000000,750000000,77000000,-2000000,-73000000,-99000000,14000000,-176000000,532000000.0,en-US,US,EQUITY,True,Delayed Quote,USD,"IQVIA Holdings, Inc.",0.15300392,50259263488,26.595337,8.439975,15,America/New_York,EDT,-14400000,False,False,PRE,0,2,4.319977,1.6473999,262.23,1630526573,2.5,260.01,263.05,258.48,497947,NYQ,us_market,1630570149,266.55,0.962538,258.48 - 263.05,259.73,0.0,0.0,8,8,finmb_137473239,NYSE,IQVIA Holdings Inc.,USD,886662,545057,116.23001,0.79609597,146.0 - 263.61,-1.3799744,-0.0052349092,146.0,263.61,1619094600,1634560200,1634905800,124.87144,2.1,9.86,8.83,29.697622,31.07,250.42114,11.808868,0.047156036,227.43202,34.79799,1.45,,,263.61,146.0,250.42,227.43,886.66k,545.06k,191.66M,,190.23M,0.72%,91.22%,2.63M,2.55,1.56%,1.38%,2.59M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",4.69%,9.02%,3.09%,10.85%,12.93B,67.54,36.40%,3.86B,2.23B,607M,2.10,,1.91B,9.97,12.67B,220.04,1.05,31.07,2.73B,2.34B,Value,06810,Healthcare,74000,10,5,"IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",Danbury,203 448 4600,CT,9,1609372800,1625097600,10,United States,http://www.iqvia.com,86400,10,83 Wooster Heights Road,Diagnostics & Research
t-3,IQV,-11739000000.0,191660992,,,105000000,261000000.0,101000000,460000000,986000000,207000000,207000000,,-100000000,,,,-3000000,2786000000,2579000000,1800000000,-102000000,,108000000,101000000,5222000000.0,11067000000.0,17730000000.0,5846000000.0,1380000000.0,23837000000.0,3000000.0,445000000.0,1158000000.0,829000000.0,12363000000.0,-6382000000.0,502000000.0,1464000000.0,4139000000.0,125000000.0,144000000.0,-317000000.0,942000000.0,4645000000.0,163000000.0,79000000.0,2492000000.0,12255000000.0,2461000000.0,-8000000,0,-191000000,-36000000,-53000000,53000000,355000000,-101000000,25000000,574000000,319000000,-2000000,120000000,-17000000,-24000000,-157000000,506000000.0,en-US,US,EQUITY,True,Delayed Quote,USD,"IQVIA Holdings, Inc.",0.15300392,50259263488,26.595337,8.439975,15,America/New_York,EDT,-14400000,False,False,PRE,0,2,4.319977,1.6473999,262.23,1630526573,2.5,260.01,263.05,258.48,497947,NYQ,us_market,1630570149,266.55,0.962538,258.48 - 263.05,259.73,0.0,0.0,8,8,finmb_137473239,NYSE,IQVIA Holdings Inc.,USD,886662,545057,116.23001,0.79609597,146.0 - 263.61,-1.3799744,-0.0052349092,146.0,263.61,1619094600,1634560200,1634905800,124.87144,2.1,9.86,8.83,29.697622,31.07,250.42114,11.808868,0.047156036,227.43202,34.79799,1.45,,,263.61,146.0,250.42,227.43,886.66k,545.06k,191.66M,,190.23M,0.72%,91.22%,2.63M,2.55,1.56%,1.38%,2.59M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",4.69%,9.02%,3.09%,10.85%,12.93B,67.54,36.40%,3.86B,2.23B,607M,2.10,,1.91B,9.97,12.67B,220.04,1.05,31.07,2.73B,2.34B,Value,06810,Healthcare,74000,10,5,"IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",Danbury,203 448 4600,CT,9,1609372800,1625097600,10,United States,http://www.iqvia.com,86400,10,83 Wooster Heights Road,Diagnostics & Research
